Millennium Management’s Virax Biolabs VRAX Stock Holding History

Millennium Management’s Portfolio VRAX Stock Details VRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-50	Closed	-$4.9K	–	6614
2023 Q2	$4.9K	Buy	+50	New	+$5.5K	﹤0.01%	5867
2023 Q1	–	Sell	-62	Closed	-$11K	–	6901
2022 Q4	$11K	Buy	+62	New	+$22K	﹤0.01%	6171

Other funds holding VRAX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Millennium Management's VRAX Position: Q3 2023 in Review

Millennium Management sold out of Virax Biolabs (VRAX) in Q3 2023, closing a stake of 50 shares — an estimated $4.9K sold.

Millennium Management first reported a position in VRAX in Q4 2022 and held it in 2 quarters. The position peaked at $11K in Q4 2022. 4 funds tracked by Wall St. Rank hold VRAX as of Q3 2023.

Millennium Management reported no remaining Virax Biolabs position as of Q3 2023 after selling out during the quarter.
Millennium Management sold 50 Virax Biolabs shares in Q3 2023, an estimated $4.9K.
Millennium Management first reported a position in Virax Biolabs in Q4 2022 and held it in 2 quarters.
Millennium Management's Virax Biolabs position peaked at $11K in Q4 2022.
4 funds tracked by Wall St. Rank held Virax Biolabs as of Q3 2023.

Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.